Anti-Human CD248 Antibody (SAA0182)

Catalog No.

FHJ61010

Species reactivity

Human

Host species

Human

Isotype

IgG1, kappa

Clonality

Monoclonal

Conjugation

Unconjugated

Target

Endosialin, TEM1, CD164L1, Tumor endothelial marker 1, CD248

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q9HCU0

Applications

FCM

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

SAA0182

Corrigendum to "CXCL12 derived from CD248-expressing cancer-associated fibroblasts mediates M2-polarized macrophages to promote nonsmall cell lung cancer progression" [Biochim. Biophys. Acta Mol. Basis Dis., 1868 (2022) 166521-166521/10.1016/j.bbadis.2022.166521]., PMID:40287323

Dynamic molecular atlas of cardiac fibrosis at single-cell resolution shows CD248 in cardiac fibroblasts orchestrates interactions with immune cells., PMID:40148545

CD248-targeted BBIR-T cell therapy against late-activated fibroblasts in cardiac repair after myocardial infarction., PMID:40148319

Endosialin-positive CAFs promote hepatocellular carcinoma progression by suppressing CD8+ T cell infiltration., PMID:39260826

CD248-expressing cancer-associated fibroblasts induce non-small cell lung cancer metastasis via Hippo pathway-mediated extracellular matrix stiffness., PMID:39164826

CD248 interacts with ECM to promote hypertrophic scar formation and development., PMID:38944165

CD248-expressing cancer-associated fibroblasts induce epithelial-mesenchymal transition of non-small cell lung cancer via inducing M2-polarized macrophages., PMID:38906929

IL-8 from CD248-expressing cancer-associated fibroblasts generates cisplatin resistance in non-small cell lung cancer., PMID:38396325

TEM1/endosialin/CD248 promotes pathologic scarring and TGF-β activity through its receptor stability in dermal fibroblasts., PMID:38254097

Endosialin in Cancer: Expression Patterns, Mechanistic Insights, and Therapeutic Approaches., PMID:38164138

[Expression of endosialin in human hypertrophic scars and its regulation on fibroblast phenotype]., PMID:38129304

[IgG78-DM1 inhibits pulmonary fibrosis by targeting and killing CD248-positive myofibroblasts in mice]., PMID:37732571

Endosialin-positive tumor-derived pericytes promote tumor progression through impeding the infiltration of CD8+ T cells in clear cell renal cell carcinoma., PMID:36646951

Soluble tumor endothelial marker 1 in heart failure with reduced ejection fraction: A pilot study., PMID:36588577

CXCL12 derived from CD248-expressing cancer-associated fibroblasts mediates M2-polarized macrophages to promote nonsmall cell lung cancer progression., PMID:35985448

Antibody-drug conjugates targeting CD248 inhibits liver fibrosis through specific killing on myofibroblasts., PMID:35317721

TEM1-targeting PEGylated PLGA shikonin nanoformulation for immunomodulation and eradication of ovarian cancer., PMID:35087718

Endosialin/CD248 may be a potential therapeutic target to prevent the invasion and metastasis in osteosarcoma., PMID:34976154

Antibody-drug conjugates targeting CD248+ myofibroblasts effectively alleviate renal fibrosis in mice., PMID:34972243

Soluble trivalent engagers redirect cytolytic T cell activity toward tumor endothelial marker 1., PMID:34467246

Endosialin (CD248) Expression in Fibromas and Soft-tissue Fibrosarcomas in Dogs., PMID:33910824

CD248 enhances tissue factor procoagulant function, promoting arterial and venous thrombosis in mouse models., PMID:33830628

Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies., PMID:33807678

Biological evaluation of new TEM1 targeting recombinant antibodies for radioimmunotherapy: In vitro, in vivo and in silico studies., PMID:33271301

Oxidative Stress Product, 4-Hydroxy-2-Nonenal, Induces the Release of Tissue Factor-Positive Microvesicles From Perivascular Cells Into Circulation., PMID:33028097

CD248 as a novel therapeutic target in pulmonary arterial hypertension., PMID:32997414

Interaction with CD68 and Regulation of GAS6 Expression by Endosialin in Fibroblasts Drives Recruitment and Polarization of Macrophages in Hepatocellular Carcinoma., PMID:32591411

Preclinical Evaluation and Dosimetry of [111In]CHX-DTPA-scFv78-Fc Targeting Endosialin/Tumor Endothelial Marker 1 (TEM1)., PMID:31993928

Linking myofibroblast generation and microvascular alteration: The role of CD248 from pathogenesis to therapeutic target (Review)., PMID:31257535

A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas., PMID:31034598

CD248: A therapeutic target in cancer and fibrotic diseases., PMID:30847027

A phase I study of ontuxizumab, a humanized monoclonal antibody targeting endosialin, in Japanese patients with solid tumors., PMID:30623276

Tumour endothelial marker 1/endosialin-mediated targeting of human sarcoma., PMID:29304474

Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213)., PMID:29292843

A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma., PMID:29127533

Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma., PMID:28947977

Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy., PMID:27933426

Novel antibody probes for the characterization of endosialin/TEM-1., PMID:27494870

Endosialin expression in soft tissue sarcoma as a potential marker of undifferentiated mesenchymal cells., PMID:27434038

Endosialin and Associated Protein Expression in Soft Tissue Sarcomas: A Potential Target for Anti-Endosialin Therapeutic Strategies., PMID:27057137

Development of 89Zr-Ontuxizumab for in vivo TEM-1/endosialin PET applications., PMID:26909615

Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature., PMID:26327620

Targeting tumor vasculature: expanding the potential of DNA cancer vaccines., PMID:26267042

Anti-Endosialin Antibody-Drug Conjugate: Potential in Sarcoma and Other Malignancies., PMID:26184481

Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications., PMID:26085332

A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumors., PMID:25398449

Development, optimization, and validation of novel anti-TEM1/CD248 affinity agent for optical imaging in cancer., PMID:25051365

Shikonin-loaded antibody-armed nanoparticles for targeted therapy of ovarian cancer., PMID:24790428

Antibody-based tumor vascular theranostics targeting endosialin/TEM1 in a new mouse tumor vascular model., PMID:24553243

Characterisation of fibroblast-like synoviocytes from a murine model of joint inflammation., PMID:23363614

Document Download

Anti-Human CD248 Antibody (SAA0182).pdf